分组1 - Waters reported quarterly earnings of $4.53 per share, exceeding the Zacks Consensus Estimate of $4.5 per share, and up from $4.1 per share a year ago, representing an earnings surprise of +0.74% [1] - The company achieved revenues of $932.36 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.55%, and an increase from $872.71 million year-over-year [2] - Over the last four quarters, Waters has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Waters shares up about 0.4% year-to-date compared to the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $2.54 on revenues of $713.34 million, and for the current fiscal year, it is $14.25 on revenues of $3.36 billion [7] - The Medical - Instruments industry, to which Waters belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Mettler-Toledo (MTD) came out with quarterly earnings of $13.36 per share, beating the Zacks Consensus Estimate of $12.76 per share. This compares to earnings of $12.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.67%. A quarter ago, it was expected that this maker of precision instruments would post earnings of $10.62 per share when it actually produced earnings of $11.15, delivering a surprise of +4.99%.Over the last f ...

IQVIA Holdings (IQV) came out with quarterly earnings of $3.42 per share, beating the Zacks Consensus Estimate of $3.4 per share. This compares to earnings of $3.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.50%. A quarter ago, it was expected that this clinical testing company would post earnings of $2.96 per share when it actually produced earnings of $3, delivering a surprise of +1.35%.Over the last four quarters, t ...

Core Viewpoint - IDEXX Laboratories, Inc. is a leading player in the animal diagnostics industry, showcasing strong financial performance and exceeding market expectations in its latest earnings report for Q4 2025 [1] Financial Performance - IDEXX reported an earnings per share (EPS) of $3.08 for Q4 2025, surpassing the Zacks Consensus Estimate of $2.93, and showing a significant increase from $2.62 EPS in the same quarter the previous year, with an earnings surprise of +5.17% [2] - The company achieved approximately $1.09 billion in revenue for the quarter ending December 2025, exceeding the Zacks Consensus Estimate by 1.86%, and representing a notable increase from $954.29 million in revenue reported a year ago [2] Revenue Growth - Revenue growth was primarily driven by the Companion Animal Group (CAG), which reported a 15% increase in revenue and a 13% organic growth [3] Financial Metrics - IDEXX has a price-to-earnings (P/E) ratio of approximately 50.82, indicating that investors are willing to pay over 50 times the company's earnings for its shares [3] - The price-to-sales ratio stands at about 12.49, suggesting that the market values the company at over 12 times its annual sales [3] - The company's debt-to-equity ratio is approximately 0.71, indicating a moderate level of debt compared to its equity [3] - IDEXX demonstrates a reasonable level of short-term financial health with a current ratio of about 1.12, having slightly higher current assets compared to current liabilities [3]

Idexx Laboratories (IDXX) came out with quarterly earnings of $3.08 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $2.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.17%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $3.14 per share when it actually produced earnings of $3.4, delivering a surprise of +8.28%.Over ...

Company Performance - Pacific Biosciences of California (PACB) closed at $2.26, reflecting a -4.64% change from the previous day, underperforming the S&P 500's daily loss of 0.43% [1] - Over the past month, PACB shares have gained 26.74%, while the Medical sector has lost 2.36% and the S&P 500 has gained 0.89% [1] Earnings Estimates - The company is expected to release its earnings on February 12, 2026, with projected earnings per share (EPS) of -$0.19, indicating a 5% increase from the same quarter last year [2] - Full-year Zacks Consensus Estimates predict earnings of -$1.89 per share and revenue of $0 million, representing year-over-year changes of -127.71% and 0%, respectively [3] Analyst Insights - Recent changes to analyst estimates for Pacific Biosciences should be monitored, as positive revisions are often seen as a good sign for business outlook [3] - The Zacks Rank system, which includes estimate changes, currently ranks Pacific Biosciences at 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - Hologic reported quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share, representing an earnings surprise of -4.46% [1]. Financial Performance - The company posted revenues of $1.05 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 2.14%, compared to $1.02 billion in the same quarter last year [2]. - Over the last four quarters, Hologic has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2]. Stock Performance - Hologic shares have increased by approximately 0.8% since the beginning of the year, while the S&P 500 has gained 1.9% [3]. - The current Zacks Rank for Hologic is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $1.05 billion, and for the current fiscal year, it is $4.51 on revenues of $4.28 billion [7]. - The trend of earnings estimate revisions for Hologic was mixed ahead of the earnings release, which could change following the recent report [6]. Industry Context - The Medical - Instruments industry, to which Hologic belongs, is currently in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8].

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of $6.43 per share. This compares to earnings of $6.1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.13%. A quarter ago, it was expected that this maker of scientific instrument and laboratory supplies would post earnings of $5.5 per share when it actually produced earnings of $5.79, delivering a surpris ...

Core Insights - Veracyte (VCYT) is positioned to continue its earnings-beat streak, having surpassed earnings estimates by an average of 50.66% in the last two quarters [1] Earnings Performance - In the last reported quarter, Veracyte achieved earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, resulting in a surprise of 59.38% [2] - In the previous quarter, the company was expected to report earnings of $0.31 per share but delivered $0.44 per share, leading to a surprise of 41.94% [2] Earnings Estimates and Predictions - Recent estimates for Veracyte have been trending upward, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better historically results in a positive surprise nearly 70% of the time [6] Earnings ESP Analysis - Veracyte currently has an Earnings ESP of +7.98%, suggesting increased analyst optimism regarding its near-term earnings potential [8] - The positive Earnings ESP, combined with a Zacks Rank of 1 (Strong Buy), indicates a high probability of another earnings beat [8]

Company Performance - Pacific Biosciences of California (PACB) closed at $2.58, reflecting a decrease of -3.37% from the previous day's closing price, underperforming the S&P 500's daily gain of 0.03% [1] - Over the past month, PACB shares have increased by 42.02%, outperforming the Medical sector's slight loss of -0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts anticipate that Pacific Biosciences will report earnings of -$0.19 per share, indicating a year-over-year growth of 5% [2] - For the entire fiscal year, the Zacks Consensus Estimates project earnings of -$1.89 per share and revenue of $0 million, representing changes of -127.71% and 0% from the prior year, respectively [2] Analyst Estimates - Recent changes to analyst estimates for Pacific Biosciences reflect shifting short-term business dynamics, with positive revisions indicating optimism about the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides an actionable rating system for investors [4] Zacks Rank and Industry Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Pacific Biosciences currently holds a Zacks Rank of 3 (Hold), with the consensus EPS projection remaining stagnant over the past 30 days [5] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 92, placing it in the top 38% of all industries [6]